NAGE Niagen Bioscience, Inc.
Company Analysis
Latest News
🟢 Niagen Bioscience is trading 9.33% up in pre-market
Niagen Bioscience is trading at $2.93, up 9.33% in pre-market, with broader market gains potentially supporting the move; no company-specific catalyst has...
🔴 Niagen Bioscience is trading 5% down
Niagen Bioscience is trading 5.31% down now at $2.77, with no company-specific announcement or catalyst surfaced for October 1, 2026. - A market listing...
🔴 Niagen Bioscience is trading 5.02% down today as biotech ETF XBI falls 4.24%
Niagen Bioscience is trading now at $3.12, down 5.02%, with sector pressure the primary explanation after no clear company-specific catalyst emerged on August...
🔴 Niagen Bioscience is trading 6.23% down in pre-market with no clear catalyst identified
Niagen Bioscience is trading 6.23% down at $3.01 after falling from the August 27 close of $3.21, with no clear catalyst identified. - No credible August 28,...
Niagen Bioscience expands Tru Niagen retail reach, meeting healthy aging demand
Niagen Bioscience launched its flagship Tru Niagen® NAD+ supplement at GNC and Sam's Club stores and websites. This expansion adds nearly 300 retail locations...
🟢 Niagen Bioscience rises 5.4% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
Niagen Bioscience's Revenue Miss Raises a Hard Question: Can Online Supplement Sales Alone Carry a $270 Million Company?
Shares plunged 8.4% to $3.18 after hours as Niagen Bioscience's second-quarter results exposed a widening crack between the company's fastest-growing channel...
🟢 Niagen Bioscience is trading 6.5% up in pre-market after rebounding from August 6 close
Niagen Bioscience is trading at $3.24, up +6.47% in pre-market after closing at $3.04 on August 6, 2026. - No major company-specific announcement was...
🔴 Niagen Bioscience is trading 15.9% down today after Q2 revenue miss and rising marketing expenses
Niagen Bioscience is trading 15.9% down at $3.12 after its Q2 revenue missed analyst estimates and marketing costs surged. • Net sales reached $29.8 million,...
🔴 Niagen Bioscience is trading 8.4% down today after Q2 revenue missed analyst estimates
Niagen Bioscience is trading at $3.18 (-8.36%) after hours following second-quarter results that disappointed on the top line. • The company reported $29.8...
Niagen Bioscience's second quarter revenue misses estimates while strong DTC growth supports in-line EPS.
Niagen Bioscience reported second quarter 2026 net sales of $29.8 million, missing analyst expectations, while diluted earnings per share came in at $0.01,...
Niagen Bioscience, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
Analysts expect Niagen Bioscience to report Q2 2026 revenue of approximately $32.00 million and earnings per share of $0.01, while the stock currently trades...